Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.

ABSTRACT:

Background

While insulin is the standard of care for feline diabetes mellitus (FDM), non-insulin antidiabetic drugs (NIADs) are emerging as alternatives. This systematic review aims to synthesize and critically appraise the current evidence for the efficacy and safety of NIADs in cats.

Methods

A systematic review was conducted following PRISMA guidelines. Major databases were searched for studies evaluating NIADs in diabetic cats or at-risk/experimental models. Risk of bias was assessed using RoB 2 and ROBINS-I tools.

Results

Twenty studies were included. In diabetic cats (10 studies), traditional agents (glipizide, metformin, acarbose) showed limited efficacy based on evidence with a high risk of bias. Newer SGLT2 inhibitors (bexagliflozin, velagliflozin) demonstrate

SUBMITTER: Romero-Velez F 

PROVIDER: S-EPMC12427183 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature